European Medicines Agency to review lonafarnib for progeria and progeroid laminopathies

Regulatory review will begin for this first-in-class, oral inhibitor of farnesyltransferase. A recent study found lonafarnib demonstrated an 88% reduction in risk of mortality in patients with Progeria, an ultra-rare and fatal genetic condition of accelerated aging in children


Biospace Inc.